Los Angeles, CA -- (SBWire) -- 04/17/2019 --Glucagon like peptide-1 (GLP-1) agonists is the agonists of the GLP-1 receptor. This class of drugs is used for the treatment of type 2 diabetes. One of their advantages is over older insulin secretagogues, such as sulfonylureas or meglitinides, and they have a lower risk of causing hypoglycemia.

United States is the largest consumer of Glucagon like peptide-1 (GLP-1) agonists with the production market share of 35% and the consumption market share of 44% in 2015.

The second place is Europe, following North America with the production market share of 63% and the consumption market share of 28% in 2015.

Market competition is intense. Novo Nordisk, AstraZeneca, Eli Lilly, GSK, Sanofi are the leader of the industry, and hold the key technologies and patents, with high-end customers. They have formed global market channel of the industry. However, with the future expanding market, there will be more manufacturers in the future.

The global Glucagon Like Peptide-1 (GLP-1) Agonists market was 5240 million US$ in 2018 and is expected to 14200 million US$ by the end of 2025, growing at a CAGR of 13.3% between 2019 and 2025.

This report studies the Glucagon Like Peptide-1 (GLP-1) Agonists market size (value and volume) by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025; This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Get PDF template of this report: https://www.qyresearch.com/sample-form/form/1091750/global-glucagon-like-peptide-1-glp-1-agonists-market

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Glucagon Like Peptide-1 (GLP-1) Agonists in these regions, from 2014 to 2025, covering

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)

South America (Brazil etc.)

Middle East and Africa (Egypt and GCC Countries)

The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in this market include

Novo Nordisk

AstraZeneca

Eli Lilly

GSK

Sanofi

Bristol-Myers Squibb

Amylin

By the product type, the market is primarily split into

Exenatied

Liraglutide

Lixisenatide

Albiglutide

Dulaglutide

By the end users/application, this report covers the following segments

Hospital

Pharmacy

Other

We can also provide the customized separate regional or country-level reports, for the following regions:

North America

United States

Canada

Mexico

Asia-Pacific

China

India

Japan

South Korea

Australia

Indonesia

Singapore

Malaysia

Philippines

Thailand

Vietnam

Rest of Asia-Pacific

Europe

Germany

France

UK

Italy

Spain

Russia

Rest of Europe

Central & South America

Brazil

Rest of Central & South America

Middle East & Africa

GCC Countries

Turkey

Egypt

South Africa

Rest of Middle East & Africa

Get Full Report Now at USD 3,550 @ https://www.qyresearch.com/settlement/pre/2d7ae620aff1237b2cac34657c4e64f8,0,1,Global%20Glucagon%20Like%20Peptide-1%20(GLP-1)%20Agonists%20Market%20Report,%20History%20and%20Forecast%202014-2025,%20Breakdown%20Data%20by%20Manufacturers,%20Key%20Regions,%20Types%20and%20Application

About QYResearch
QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in the consulting industry.